| Company Name: | Amgen Inc | | Ticker Symbol: | AMGN | | | WWW Address: | www.Amgen.com |
| CEO: | Mr. Robert A. Bradway | | No. of Employees: | 18,000 |
| Common Issue Type: | CS | | Business Description: | Amgen Inc. is a biotechnology medicines company. It discovers, develops, manufactures and delivers innovative human therapeutics.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 102.21 |  -3.42 | 101.66 | 102.1 | 105.33 | 105.50 | 101.26 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 76,655.1 | 750.0 | 0.41 | 5.52 | 1.44 | 17.3 | 1.8 | 114.95 - 67.61 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 102.18 | $ | | PE Ratio - LTM | 17.3 | |
| Market Capitalisation | 76,655.1 | mil |
| Latest Shares Outstanding | 750.0 | mil |
| Earnings pS (EPS) | 5.52 | $ |
| Dividend pS (DPS) | 1.44 | ¢ |
| Dividend Yield | 1.8 | % |
| Dividend Payout Ratio | 26 | % |
| Revenue per Employee | 959,167 | $ |
| Effective Tax Rate | 13.3 | % |
| Float | 748.8 | mil |
| Float as % of Shares Outstanding | 99.9 | % |
| Foreign Sales | 3,850 | mil |
| Domestic Sales | 13,415 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 28.00 | % |
| Research & Devlopment (R&D) as % of Revenue | 20.20 | % |
| Gross Profit Margin | 88.0 | % |
| EBITDA Margin | 39.8 | % |
| Pre-Tax Profit Margin | 28.6 | % |
| Assets Turnover | 0.3 | % |
| Return on Assets (ROA) | 13.6 | % |
| Return on Equity (ROE) | 36.1 | % |
| Return on Capital Invested (ROCI) | 16.2 | % |
| Current Ratio | 5.6 | |
| Leverage Ratio (Assets/Equity) | 2.6 | |
| Interest Cover | 9.1 | |
| Total Debt/Equity (Gearing Ratio) | 1.23 | |
| LT Debt/Total Capital | 55.0 | % |
| Working Capital pS | 31.40 | $ |
| Cash pS | 3.37 | $ |
| Book-Value pS | 25.99 | $ |
| Tangible Book-Value pS | 3.99 | $ |
| Cash Flow pS | 10.87 | $ |
| Free Cash Flow pS | 3.53 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.93 | |
| Price/Tangible Book Ratio | 25.63 | |
| Price/Cash Flow | 9.4 | |
| Price/Free Cash Flow | 28.9 | |
| P/E as % of Industry Group | 66.0 | % |
| P/E as % of Sector Segment | 14.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 03/05/2013 |
| Dividend Ex-Date | 05/13/2013 |
| Dividend Record Date | 05/15/2013 |
| Dividend Pay Date | 06/06/2013 |
| Dividend Amount | 470 |
| Type of Payment | Cash Payment |
| Dividend Rate | 1.88 |
| Current Dividend Yield | 1.8 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 26.0 |
| 5-Y Average Payout Ratio | 8.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -3.3 | 97 | 31,257 | 38,900 |
| 4 Weeks | 109.56 | 101.26 | 108.38 | -5.7 | 90 | 33,086 | 529,368 |
| 13 Weeks | 114.95 | 88.66 | 86.82 | 17.7 | 107 | 42,741 | 2,564,460 |
| 26 Weeks | 114.95 | 81.56 | 87.60 | 16.6 | 99 | 48,314 | 5,845,969 |
| 52 Weeks | 114.95 | 67.61 | 69.05 | 48.0 | 117 | 46,314 | 11,346,932 |
| YTD | 114.95 | 81.56 | - | 18.5 | 101 | 50,977 | 4,893,831 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 105.63 | 105.58 | 104.68 | 93.03 | 90.32 | 0.41 | 0.54 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 2.99 | 71.9 | 4.89 |
| Income | 9.74 | 68.4 | 4.85 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 12.12 | NA | 83.32 |
| R&D | 1.62 | NA | 6.10 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 4.7 | 4.7 | 10.8 |
| Earnings % | 21.1 | 21.1 | 0.0 |
| EPS % | 27.0 | 27.0 | 36.6 |
| EPS $ | 0.40 | 0.40 | 1.48 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 42.39 |
| Current Ratio | 3.8 |
| Quick Ratio (Acid Test) | 3.2 |
| Liquidity Ratio (Cash) | 2.94 |
| Receivables Turnover | 6.4 |
| Average Collection Period | 56 |
| Working Capital/Equity | 120.8 |
| Working Capital pS | 30.44 |
| Cash-Flow pS | 7.18 |
| Free Cash-Flow pS | 2.23 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 2.62 |
| Financial Leverage Ratio (Assets/Equity) | 2.8 |
| Debt Ratio | 64.9 |
| Total Debt/Equity (Gearing Ratio) | 1.39 |
| LT Debt/Equity | 1.26 |
| LT Debt/Capital Invested | 62.8 |
| LT Debt/Total Liabilities | 68.2 |
| Interest Cover | 5.8 |
| Interest/Capital Invested | 2.28 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 25.21 |
| Tobin's Q Ratio | 1.41 |
| Current P/E Ratio - LTM | 17.30 |
| Enterprise Value (EV)/EBITDA | 12.62 |
| Enterprise Value (EV)/Free Cash Flow | 41.45 |
| Dividend Yield | 1.8 |
| Price/Tangible Book Ratio - LTM | 25.63 |
| Price/Book Ratio - LTM | 3.93 |
| Price/Cash Flow Ratio | 9.4 |
| Price/Free Cash Flow Ratio - LTM | 28.9 |
| Price/Sales Ratio | 4.39 |
| P/E Ratio (1 month ago) - LTM | 18.8 |
| P/E Ratio (26 weeks ago) - LTM | 15.7 |
| P/E Ratio (52 weeks ago) - LTM | 16.0 |
| 5-Y High P/E Ratio | 17.1 |
| 5-Y Low P/E Ratio | 10.0 |
| 5-Y Average P/E Ratio | 14.1 |
| Current P/E Ratio as % of 5-Y Average P/E | 123 |
| P/E as % of Industry Group | 66.0 |
| P/E as % of Sector Segment | 14.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 17.3 |
| PER SHARE FIGURES |
| LT Debt pS | 31.78 |
| Current Liabilities pS | 10.83 |
| Tangible Book Value pS - LTM | 3.99 |
| Book Value pS - LTM | 25.99 |
| Capital Invested pS | 57.46 |
| Cash pS - LTM | 3.37 |
| Cash Flow pS - LTM | 10.87 |
| Free Cash Flow pS - LTM | 3.53 |
| Earnings pS (EPS) | 5.52 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 9.76 |
| Free Cash Flow Margin 5YEAR AVG | 28.11 |
| Net Profit Margin | 25.2 |
| Net Profit Margin - 5YEAR AVRG. | 17.0 |
| Equity Productivity | 0.91 |
| Return on Equity (ROE) | 22.8 |
| Return on Equity (ROE) - 5YEAR AVRG. | 12.5 |
| Capital Invested Productivity | 0.40 |
| Return on Capital Invested (ROCI) | 10.1 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 7.3 |
| Assets Productivity | 0.30 |
| Return on Assets (ROA) | 8.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | 5.9 |
| Gross Profit Margin | 88.0 |
| Gross Profit Margin - 5YEAR AVRG. | 89.5 |
| EBITDA Margin - LTM | 39.8 |
| EBIT Margin - LTM | 33.8 |
| Pre-Tax Profit Margin | 29.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 32.1 |
| Effective Tax Rate | 13.3 |
| Effective Tax Rate - 5YEAR AVRG. | 13.8 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 495 |
| Revenue per Employee | 959,167 |
| Net Income per Employee | 241,389 |
| Average Collection Period | 53 |
| Receivables Turnover | 6.4 |
| Day's Inventory Turnover Ratio | 443 |
| Inventory Turnover | 0.8 |
| Inventory/Sales | 15.9 |
| Accounts Payble/Sales | 19.69 |
| Assets/Revenue | 3.33 |
| Net Working Capital Turnover | 0.75 |
| Fixed Assets Turnover | 0.75 |
| Total Assets Turnover | 0.3 |
| Revenue per $ Cash | 5.30 |
| Revenue per $ Plant | 3.24 |
| Revenue per $ Common Equity | 0.91 |
| Revenue per $ Capital Invested | 0.40 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 27.8 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 27.1 |
| Research & Devlopment (R&D) as % of Revenue | 19.6 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 19.6 |
|
|  
| | |  |  | |
| |
